These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 29768542)

  • 1. [Not Available].
    Siqueira-Neto JL
    Rev Soc Bras Med Trop; 2018; 51(2):123-124. PubMed ID: 29768542
    [No Abstract]   [Full Text] [Related]  

  • 2. Chagas' disease.
    Montero A; Giovannoni AG
    Lancet; 2001 Jul; 358(9275):74. PubMed ID: 11458940
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of Chagas disease with benznidazole and thioctic acid].
    Roldán EJ
    Medicina (B Aires); 2005; 65(1):85-6; author reply 86-7. PubMed ID: 15830800
    [No Abstract]   [Full Text] [Related]  

  • 4. The present situation, challenges, and perspectives regarding the production and utilization of effective drugs against human Chagas disease.
    Dias JC; Coura JR; Yasuda MA
    Rev Soc Bras Med Trop; 2014; 47(1):123-5. PubMed ID: 24603750
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of Chagas disease].
    Abitbol H
    An R Acad Nac Med (Madr); 1981; 98(4):755-8. PubMed ID: 6808853
    [No Abstract]   [Full Text] [Related]  

  • 6. The need of a neonatal preparation for Chagas disease.
    Sosa-Estani S; Belizan JM; Althabe F; Rubinstein A
    PLoS Med; 2005 Nov; 2(11):e387. PubMed ID: 16288560
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitrypanosomal agents: treatment or threat?
    Issa VS; Bocchi EA
    Lancet; 2010 Sep; 376(9743):768; author reply 768-9. PubMed ID: 20816538
    [No Abstract]   [Full Text] [Related]  

  • 8. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.
    Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R
    Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to different benznidazole doses in animal models of chronic phase Chagas disease: a critical review.
    Scarim CB; Ribeiro AR; Rosa JAD; Chin CM
    Rev Soc Bras Med Trop; 2018; 51(2):133-140. PubMed ID: 29768544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
    Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
    Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of a patient since the acute phase of Chagas disease (South American trypanosomiasis): further treatment and cure of the infection.
    Dias JC; Dias E; Nóbrega GC
    Rev Soc Bras Med Trop; 2015; 48(5):629-32. PubMed ID: 26516979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential new clinical therapies for Chagas disease.
    Bustamante JM; Tarleton RL
    Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing the treatment for Chagas' disease.
    Albajar-Viñas P; Dias JC
    N Engl J Med; 2014 May; 370(20):1942-3. PubMed ID: 24827039
    [No Abstract]   [Full Text] [Related]  

  • 14. First century of Chagas' disease: an overview on novel approaches to nifurtimox and benzonidazole delivery systems.
    Salomon CJ
    J Pharm Sci; 2012 Mar; 101(3):888-94. PubMed ID: 22161779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole.
    Fernández ML; Marson ME; Ramirez JC; Mastrantonio G; Schijman AG; Altcheh J; Riarte AR; Bournissen FG
    Mem Inst Oswaldo Cruz; 2016 Mar; 111(3):218-21. PubMed ID: 26982179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.
    Morilla MJ; Romero EL
    Nanomedicine (Lond); 2015 Feb; 10(3):465-81. PubMed ID: 25707979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
    Rodríguez-Guardado A; Tuset M; Asensi V; Miró JM
    Med Clin (Barc); 2011 Sep; 137(6):278-9. PubMed ID: 20980024
    [No Abstract]   [Full Text] [Related]  

  • 20. Multi-kinetic release of benznidazole-loaded multiparticulate drug delivery systems based on polymethacrylate interpolyelectrolyte complexes.
    García MC; Martinelli M; Ponce NE; Sanmarco LM; Aoki MP; Manzo RH; Jimenez-Kairuz AF
    Eur J Pharm Sci; 2018 Jul; 120():107-122. PubMed ID: 29705213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.